Darzalex Faspro

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Darzalex Faspro
Generic name
DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)
Manufacturer
Janssen Biotech, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
4bb241af-4299-4373-8762-2d6709515db0
SPL ID
7f8d76d6-da40-408e-8dcc-e16df836db77
Version
34
Effective date
2026-10-12
Source export date
2026-11-13
Source partition
7
Source file
https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:34:49
Harmonized routes table
Harmonized routes
SUBCUTANEOUS

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity and Other Administration Reactions : Permanently discontinue DARZALEX FASPRO for life-threatening reactions. ( 5.1 ) Cardiac Toxicity in Patients with Light Chain (AL) Amyloidosis : Monitor patients with cardiac involvement more frequently for cardiac adverse reactions and administer supportive care as appropriate. ( 5.2 ) Infections : DARZALEX FASPRO can cause serious and fatal infections. Monitor patients for signs and symptoms of infection and treat appropriately. ( 5.3 ) Neutropenia : Monitor complete blood cell counts periodically during treatment. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO to allow recovery of neutrophils. ( 5.4 ) Thrombocytopenia : Monitor complete blood cell counts periodically during treatment. Consider withholding DARZALEX FASPRO to allow recovery of platelets. ( 5.5 ) Embryo-Fetal Toxicity : Can cause fetal harm. Advise pregnant women of the potential risk to a fetus and advise females of reproductive potential to use effective contraception. ( 5.6 , 8.1 , 8.3 ) Interference with cross-matching and red blood cell antibody screening : Type and screen patients prior to starting treatment. Inform blood banks that a patient has received DARZALEX FASPRO. ( 5.7 , 7.1 ) 5.1 Hypersensitivity and Other Administration Reactions Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO [see Adverse Reactions (6.2) ] . Systemic Reactions In a pooled safety population of 1446 patients with multiple myeloma (N=1253) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO as monotherapy or as part of a combination therapy, 7% of patients experienced a systemic administration-related reaction (Grade 2: 3%, Grade 3: 0.8%, Grade 4: 0.1%). In patients with high-risk smoldering multiple myeloma (N=193), systemic administration-related reactions occurred in 17% of patients in AQUILA (Grade 2: 7%, Grade 3: 1%). In all patients (N=1639), systemic administration-related reactions occurred in 7% of patients with the first injection, 0.5% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 283 systemic administration-related reactions that occurred in 135 patients, 240 (85%) occurred on the day of DARZALEX FASPRO administration. Delayed systemic administration-related reactions have occurred in 1% of the patients. Severe reactions include hypoxia, dyspnea, hypertension, and tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision. Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids [see Dosage and Administration (2.6) ] . Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions [see Dosage and Administration (2.6) ] . Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO. Local Reactions In this pooled safety population of 1446 patients with multiple myeloma (N=1253) or light chain (AL) amyloidosis (N=193), injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 1.1%. The most frequent (>1%) injection-site reactions were injection site erythema and injection site rash. In patients with high-risk smoldering multiple myeloma (N=193), injection-site reactions occurred in 28% of patients, including Grade 2 reactions in 3%. These local reactions occurred a median of 6 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO. Monitor for local reactions and consider symptomatic management. 5.2 Cardiac Toxicity in Patients with Light Chain (AL) Amyloidosis Serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone [see Adverse Reactions (6.1) ] . Serious cardiac disorders occurred in 16% and fatal cardiac disorders occurred in 10% of patients. Patients with NYHA Class IIIA or Mayo Stage IIIA disease may be at greater risk. Patients with NYHA Class IIIB or IV disease were not studied. Monitor patients with cardiac involvement of light chain (AL) amyloidosis more frequently for cardiac adverse reactions and administer supportive care as appropriate. 5.3 Infections DARZALEX FASPRO can cause serious, life-threatening, or fatal infections. In patients who received DARZALEX FASPRO in a pooled safety population including patients with smoldering multiple myeloma and light chain (AL) amyloidosis (N=1639), serious infections, including opportunistic infections, occurred in 24% of patients, Grade 3 or 4 infections occurred in 22%, and fatal infections occurred in 2.5%. The most common type of serious infection reported was pneumonia (8.5%). Monitor patients for signs and symptoms of infection prior to and during treatment with DARZALEX FASPRO and treat appropriately. Administer prophylactic antimicrobials according to guidelines [see Dosage and Administration (2.6) ] . 5.4 Neutropenia Daratumumab may increase neutropenia induced by background therapy [see Adverse Reactions (6.1) ] . Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO, higher rates of Grade 3–4 neutropenia were observed. 5.5 Thrombocytopenia Daratumumab may increase thrombocytopenia induced by background therapy [see Adverse Reactions (6.1) ] . Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO until recovery of platelets. 5.6 Embryo-Fetal Toxicity Based on the mechanism of action, DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose [see Use in Specific Populations (8.1 , 8.3) ] . The combination of DARZALEX FASPRO with lenalidomide, thalidomide or pomalidomide is contraindicated in pregnant women, because lenalidomide, thalidomide or pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide or pomalidomide prescribing information on use during pregnancy. 5.7 Interference with Serological Testing Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum [see References (15) ] . The determination of a patient's ABO and Rh blood type are not impacted [see Drug Interactions (7.1) ] . Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO. Type and screen patients prior to starting DARZALEX FASPRO [see Dosage and Administration (2.1) ] . 5.8 Interference with Determination of Complete Response Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein [see Drug Interactions (7.1) ] . This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO-treated patients with IgG kappa myeloma protein.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 5 of 5 · 19 matching rows.

adverse reactions table

<table width="75%"> <caption>Table 24: Select Laboratory Abnormalities (&#x2265;20%) that Worsened from Baseline in Patients with High-Risk Smoldering Multiple Myeloma Who Received DARZALEX FASPRO in AQUILA</caption> <col width="32%" align="left" valign="top"/> <col width="17%" align="center" valign="top"/> <col width="17%" align="center" valign="top"/> <col width="17%" align="center" valign="top"/> <col width="17%" align="center" valign="top"/> <thead> <tr> <th styleCode="Lrule Rrule"/> <th colspan="2" styleCode="Botrule Rrule">DARZALEX FASPRO<footnote ID="Tb21ft">Denominator is based on number of subjects with a baseline and post-baseline laboratory value for each laboratory test: N=191 for DARZALEX FASPRO and N=191 for ACTM.</footnote> </th> <th colspan="2" styleCode="Botrule Rrule">ACTM<footnoteRef IDREF="Tb21ft"/> </th> </tr> <tr> <th styleCode="Lrule Rrule" valign="bottom">Laboratory Abnormality</th> <th styleCode="Rrule">All Grades (%) </th> <th styleCode="Rrule">Grade 3 or 4 (%)</th> <th styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grade 3 or 4 (%)</th> </tr> </thead> <tfoot> <tr> <td colspan="5" align="left" valign="top"> Key: ACTM=active monitoring</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Hematology</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased lymphocytes</td> <td styleCode="Rrule">47</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">3</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased hemoglobin</td> <td styleCode="Rrule">42</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">44</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased leukocytes</td> <td styleCode="Rrule">34</td> <td styleCode="Rrule">3</td> <td styleCode="Rrule">27</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased neutrophils</td> <td styleCode="Rrule">34</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">29</td> <td styleCode="Rrule">4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased platelets</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">1</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Chemistry</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased albumin</td> <td styleCode="Rrule">28</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Increased alanine aminotransferase (ALT)</td> <td styleCode="Rrule">25</td> <td styleCode="Rrule">1</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">1</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased sodium</td> <td styleCode="Rrule">24</td> <td styleCode="Rrule">3</td> <td styleCode="Rrule">19</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Increased creatinine</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">13</td> <td styleCode="Rrule">1</td> </tr> <tr> <td styleCode="Lrule Rrule">Increased aspartate aminotransferase (AST)</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">1</td> </tr> </tbody> </table>

adverse reactions table

<table width="75%"> <caption>Table 25: Adverse Reactions (&#x2265;10%) in Patients with AL Amyloidosis Who Received DARZALEX FASPRO with Bortezomib, Cyclophosphamide and Dexamethasone (DARZALEX FASPRO-VCd) with a Difference Between Arms of &gt;5% Compared to VCd in ANDROMEDA</caption> <col width="40%" align="left" valign="bottom"/> <col width="16%" align="center" valign="bottom"/> <col width="14%" align="center" valign="bottom"/> <col width="16%" align="center" valign="bottom"/> <col width="14%" align="center" valign="bottom"/> <thead> <tr> <th rowspan="2" styleCode="Lrule Rrule Botrule">Adverse Reaction</th> <th colspan="2" styleCode="Rrule Botrule">DARZALEX FASPRO-VCd (N=193)</th> <th colspan="2" styleCode="Rrule Botrule">VCd (N=188)</th> </tr> <tr> <th align="center" styleCode="Rrule Botrule">All Grades (%)</th> <th styleCode="Rrule Botrule">Grades 3&#x2013;4 (%)</th> <th styleCode="Rrule Botrule">All Grades (%)</th> <th styleCode="Rrule Botrule">Grades 3&#x2013;4 (%)</th> </tr> </thead> <tbody> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Infections</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Upper respiratory tract infection<footnote ID="K4859">Upper respiratory tract infection includes laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, rhinovirus infection, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection, upper respiratory tract infection bacterial, and viral upper respiratory tract infection.</footnote> </td> <td styleCode="Rrule">40</td> <td styleCode="Rrule">1<footnote ID="t19f1">Only Grade 3 adverse reactions occurred.</footnote> </td> <td styleCode="Rrule">21</td> <td styleCode="Rrule">1<footnoteRef IDREF="t19f1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Pneumonia<footnote ID="K4883">Pneumonia includes lower respiratory tract infection, pneumonia, pneumonia aspiration, and pneumonia pneumococcal.</footnote> </td> <td styleCode="Rrule">15</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">9</td> <td styleCode="Rrule">5</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Gastrointestinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Diarrhea</td> <td styleCode="Rrule">36</td> <td styleCode="Rrule">6<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">30</td> <td styleCode="Rrule">4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Constipation</td> <td styleCode="Rrule">34</td> <td styleCode="Rrule">2<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">29</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Nervous system disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Peripheral sensory neuropathy</td> <td styleCode="Rrule">31</td> <td styleCode="Rrule">3<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">2<footnoteRef IDREF="t19f1"/> </td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Dyspnea<footnote ID="K4985">Dyspnea includes dyspnea, and dyspnea exertional.</footnote> </td> <td styleCode="Rrule">26</td> <td styleCode="Rrule">4</td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">4<footnoteRef IDREF="t19f1"/> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Cough<footnote ID="K5006">Cough includes cough, and productive cough.</footnote> </td> <td styleCode="Rrule">20</td> <td styleCode="Rrule">1<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Musculoskeletal and connective tissue disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Back pain</td> <td styleCode="Rrule">12</td> <td styleCode="Rrule">2<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Arthralgia</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Muscle spasms</td> <td styleCode="Rrule">10</td> <td styleCode="Rrule">1<footnoteRef IDREF="t19f1"/> </td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">0</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">Cardiac disorders</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule"> Arrhythmia<footnote ID="K5098">Arrhythmia includes atrial flutter, atrial fibrillation, supraventricular tachycardia, bradycardia, arrhythmia, bradyarrhythmia, cardiac flutter, extrasystoles, supraventricular extrasystoles, ventricular arrhythmia, ventricular extrasystoles, atrial tachycardia, ventricular tachycardia</footnote> </td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">4</td> <td styleCode="Rrule">5</td> <td styleCode="Rrule">2</td> </tr> <tr styleCode="Botrule"> <td colspan="5" styleCode="Lrule Rrule"> <content styleCode="bold">General disorders and administration site conditions</content> </td> </tr> <tr> <td styleCode="Lrule Rrule"> Injection site reactions<footnote ID="K5124">Injection site reactions includes terms determined by investigators to be related to daratumumab injection.</footnote> </td> <td styleCode="Rrule">11</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">0</td> <td styleCode="Rrule">0</td> </tr> </tbody> </table>

adverse reactions table

<table width="75%"> <caption>Table 26: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO with Bortezomib, Cyclophosphamide and Dexamethasone (DARZALEX FASPRO-VCd) in ANDROMEDA</caption> <col width="40%" align="left" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <col width="15%" align="center" valign="bottom"/> <thead> <tr styleCode="Botrule"> <th rowspan="2" styleCode="Lrule Rrule">Laboratory Abnormality</th> <th colspan="2" styleCode="Rrule">DARZALEX FASPRO-VCd</th> <th colspan="2" styleCode="Rrule">VCd</th> </tr> <tr> <th align="center" styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades 3&#x2013;4 (%)</th> <th styleCode="Rrule">All Grades (%)</th> <th styleCode="Rrule">Grades 3&#x2013;4 (%)</th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="5" valign="top"> Denominator is based on the number of patients with a baseline and post-baseline laboratory value for each laboratory test, N=188 for DARZALEX FASPRO-VCd and N=186 for VCd.</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased lymphocytes</td> <td styleCode="Rrule">81</td> <td styleCode="Rrule">54</td> <td styleCode="Rrule">71</td> <td styleCode="Rrule">46</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased hemoglobin</td> <td styleCode="Rrule">66</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">70</td> <td styleCode="Rrule">6</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased leukocytes</td> <td styleCode="Rrule">60</td> <td styleCode="Rrule">7</td> <td styleCode="Rrule">46</td> <td styleCode="Rrule">4</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Decreased platelets</td> <td styleCode="Rrule">46</td> <td styleCode="Rrule">3</td> <td styleCode="Rrule">40</td> <td styleCode="Rrule">4</td> </tr> <tr> <td styleCode="Lrule Rrule">Decreased neutrophils</td> <td styleCode="Rrule">30</td> <td styleCode="Rrule">6</td> <td styleCode="Rrule">18</td> <td styleCode="Rrule">4</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.